Coiffier B, Bryon P A, Ffrench M, Blanc M, Sebban C, Berger F, Viala J J
Service d'Hématologie-Oncologie, Hôpital Edouard-Herriot, Lyon, France.
Blood. 1987 Nov;70(5):1394-9.
One hundred patients with aggressive malignant lymphomas treated with the LNH-80 regimen were evaluated for long-term survival and pretreatment characteristics predictive of response and survival. LNH-80 consists of three intensive courses of adriamycin cyclophosphamide vindesine bleomycin (ACVB) followed by sequential consolidation and final intensification. Eighty-four patients went into complete remission (CR), eight had a partial response (PR), three failed to respond, and five died during induction. Twenty-three patients (27%) relapsed, in two of whom a prolonged second remission was obtained. Sixty-three patients are currently alive, two of them with disease. Four patients died in CR. Median survival and median freedom from relapse survival were not reached with a median follow-up of 4 1/2 years. Characteristics negatively associated with response in multivariate analysis were: poor performance status, bone marrow involvement, and two or more extranodal sites of disease. Duration of CR was associated with splenic involvement. Three characteristics were negatively associated with survival in multivariate analysis: age, high grade subtypes, and bone marrow involvement.
对100例采用LNH - 80方案治疗的侵袭性恶性淋巴瘤患者进行了长期生存评估，并分析了预测缓解和生存的预处理特征。LNH - 80方案包括三个疗程的阿霉素、环磷酰胺、长春地辛、博来霉素（ACVB）强化治疗，随后进行序贯巩固和最终强化治疗。84例患者达到完全缓解（CR），8例部分缓解（PR），3例无反应，5例在诱导治疗期间死亡。23例患者（27%）复发，其中2例获得了延长的第二次缓解。目前63例患者存活，其中2例仍有疾病。4例患者在CR期死亡。中位随访4.5年，未达到中位生存期和无复发生存期。多因素分析中与缓解呈负相关的特征为：体能状态差、骨髓受累以及两个或更多结外病变部位。CR持续时间与脾脏受累有关。多因素分析中与生存呈负相关的三个特征为：年龄、高级别亚型和骨髓受累。
